US-Dutch raises $5.2M to scale their medical data and imaging platform

Segmed – a cloud-based real-world imaging platform seeking to accelerate innovation in healthcare by simplifying access to medical data – today announced the closing of an oversubscribed $5.2 million seed+ funding round led by Nina Capital, with participation from iGan Partners, M3 Inc, Mighty Capital, Expeditions Fund, and Alchemist Accelerator. This brings the total funds raised to more than $10 million. The company is also thrilled to report the launch of Segmed Insight from beta. 

Segmed Insight was built with the goal of getting high-quality, real-world medical imaging datasets that are linked with other data types in the hands of clinicians, researchers and developers quickly; particularly those seeking to train and/or validate their AI algorithms and models. 

Medical researchers and AI developers using Segmed Insight can conduct a search, view studies and reports that match their search criteria, and construct datasets of imaging data linked to other clinical data specific to their parameters. After placing a dataset order, users will have data in hand within a matter of days – a process that could take years prior to Segmed. Aside from this self-serve option, Segmed also offers a concierge service where their qualified team of medical specialists and clinician-scientists curate and deliver a dataset to the customer after an assessment of their requirements.

By forging partnerships with healthcare systems, hospitals and imaging clinics across 1,000 locations on 5 continents, Segmed has done all the heavy lifting when it comes to aggregating diverse medical data. 

Patient privacy and data stewardship remain top priorities at Segmed. The company maintains strict HIPAA compliance, obtained its SOC 2 attestation earlier this year, and only uses and shares fully de-identified data, ensuring that no personal information is ever exposed. 

“We have seen the healthcare industry become increasingly adoptive of artificial intelligence methods, but a major roadblock in the development of unbiased, high-performing algorithms and models has been the timely acquisition of diverse, high-quality data,” said Dr. Martin Willemink, CEO and co-founder at Segmed. “With Insight, our customers can massively cut down on data sourcing time, which in turn accelerates research and development by pharmaceutical companies, medical device companies, clinicians, academics, and CROs, among others.”

Segmed is well positioned to lower the barriers for innovation in medical AI by bridging the gap between data providers and data consumers with their Insight platform,” said Sebastian

Anastassiou, Head of Investments at Nina Capital. “This will make it easier to tackle tough healthcare problems, ultimately improving the quality of patient care in the years to come.”

1518 752 Editorial Staff
My name is HAL 9000, how can I assist you?
This website uses cookies to ensure the best possible experience. By clicking accept, you agree to our use of cookies and similar technologies.
Privacy Policy